Tempus AI (TEM) Stock Price Prediction: Bullish tape meets a near-term resistance test

Tempus AI (TEM) stock traded at $76.64, up 0.10%, near resistance at $77.32. Q3 2026 revenue was $411.5M, with oncology unit growth of 32% and Data & Applications revenue growth of 33%. Needham raised its price target to $89, citing data growth. Technical indicators show mixed momentum, with support at $75.68 and resistance at $77.32.

Original reporting
Published Nov 9, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 8:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tempus AI (TEM) Stock Price Prediction: Bullish tape meets a near-term resistance test — source image
Decision brief

The 30-second read

$TEMNeutralMed
01

Why it matters

Earnings and target raise provide a fresh catalyst, but technical resistance limits immediate upside, creating a short‑term trade range.

02

Market read

First‑report earnings with target hike give traders a new data point; price action likely to stay within $75‑$78 range pending breakout.

03

What to watch

Derivatives flow shows neutral funding and rising open interest, indicating potential for rapid moves if breakout fails.

Relevance 6/10Novelty 7/10Timing: after-hours today

Background

The article combines tokenized stock price data with fresh earnings results and analyst target adjustments for Tempus AI.

Company-level read

Ticker impact

$TEMNeutralHigh confidence
Context

Tempus AI reported Q3 2026 revenue of $411.5M and an analyst raised its price target to $89, providing fresh earnings data.

Expected impact

likely modest upside pressure as investors price in the higher target, but resistance at $77.32 could limit moves.

Evidence & confidence

The earnings numbers and target hike are new information, but the stock is still below key resistance levels, suggesting limited immediate upside.

Market effects

Positive data for AI‑driven health‑tech may boost sentiment in the broader health‑tech and data analytics sectors.

Limited to U.S. and crypto‑linked investors tracking tokenized equities.

Modest, as Tempus AI is a micro‑cap; impact confined to niche AI‑health investors.

Counterpoint

Resistance at $77.32 is strong; a break below $75.68 could trigger a short‑term sell‑off despite the earnings beat.

Key entities

  • Tempus AI

    AI‑driven oncology and data analytics firm, ticker TEM.

  • Needham

    Raised price target to $89 following earnings.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.